Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics

NEW YORK, December 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Baxter International Inc. Research Report

On November 27, 2013, Baxter International Inc. (Baxter) announced that the Company has initiated a voluntary recall of one lot of Nitroglycerin in 5% Dextrose Injection as a particulate matter was found in one vial. According to the Company, particulate matter, if infused, could lead to potential venous and/or arterial thromboembolism (blockage of blood vessels) and other adverse events including inflammation, particularly in the lungs, and local irritation of blood vessels. The Company stated that no adverse events have been reported yet regarding this issue, and the financial impact of the recall is not material to the Company. Baxter stated that it is notifying customers, directing them not to use product from the recalled lot and to locate and remove all affected product from their facility. The Company informed that affected lot was distributed to customers between January 17, 2013 and October 10, 2013, with product code 1A0694, and affected lot number G105197. Baxter added that this recall is being conducted with the knowledge of the U.S. Food and Drug Administration. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

Incyte Corporation Research Report

On November 25, 2013, Incyte Corporation (Incyte) announced that it will present at the Oppenheimer 24th Annual Healthcare Conference on December 11, 2013 at 10:40 a.m. EST in New York. Incyte stated that the presentation will be webcast live and can be accessed via Investors Relations section of the Company's website. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/076e_INCY

--

Horizon Pharma, Inc. Research Report

On November 26, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that its Chairman, President and CEO Timothy P. Walbert, will present at the Piper Jaffray 25th Annual Healthcare Conference on December 3, 2013 at 1:30 p.m. ET in New York. Horizon Pharma stated that Walbert will give an overview of the Company and its corporate activities at the conference. The Company added that a live webcast of the presentation will be available on its website, and replay of the same will be available for 10 business days. The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

--

POZEN Inc. Research Report

On November 21, 2013, POZEN Inc. (POZEN) announced that the John R. Plachetka, Company's Chairman, President and CEO, will present at the Piper Jaffray, 25th Annual Healthcare Conference on December 3, 2013 at 12:30 p.m. ET at the New York Palace Hotel. POZEN stated that the presentation will be webcast and available for replay at the Company's website. The Full Research Report on POZEN Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f226_POZN

--

IntelliPharmaCeutics International Inc. Research Report

On November 27, 2013, IntelliPharmaCeutics International Inc. (IntelliPharmaCeutics) announced an "at-the-market" offering program under which it may from time to time sell up to c.5.3 million of its common shares for up to an aggregate of US$16.8 million through at-the-market issuances on the NASDAQ Capital Market. The Company informed that Roth Capital Partners, LLC (Roth) has been engaged to act as sales agent under an equity distribution agreement, under which IntelliPharmaCeutics may at its discretion, from time to time, offer and sell common shares through Roth or directly to Roth for resale. IntelliPharmaCeutics  added that sales of common shares through Roth, if any, will be made at such time and at such price as are acceptable to the Company, from time to time, by means of ordinary brokers' transactions on the NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale or as determined by IntelliPharmaCeutics. The Company stated that it intends to use net proceeds from this offering for working capital, research and development and general corporate purposes, and to utilize up to approximately $0.8 million of any such proceeds for paying an outstanding related party loan. The Full Research Report on IntelliPharmaCeutics International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/00e6_IPCI

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED